{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:09:37Z","timestamp":1790863777844,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12072-022-10441-5","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T17:04:07Z","timestamp":1667235847000},"page":"38-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hepatitis B: \u201cTreat all\u201d or \u201cTreat select\u201d"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5582-7759","authenticated-orcid":false,"given":"Ankur","family":"Jindal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv K.","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"10441_CR1","unstructured":"World Health Organization. Hepatitis B. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b. Accessed Sep 4, 2022."},{"issue":"6","key":"10441_CR2","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","volume":"142","author":"HB El-Serag","year":"2012","unstructured":"El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.e1","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"10441_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/liv.13625","volume":"38","author":"S Shan","year":"2018","unstructured":"Shan S, Cui F, Jia J. How to control highly endemic hepatitis B in Asia. Liver Int. 2018;38(suppl 1):122\u2013125","journal-title":"Liver Int"},{"key":"10441_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398","journal-title":"Hepatol Int"},{"key":"10441_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261\u2013283","journal-title":"Hepatology"},{"key":"10441_CR6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u2013398","journal-title":"J Hepatol"},{"key":"10441_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J Am Med Assoc. 2006;295:65\u201373","journal-title":"J Am Med Assoc"},{"key":"10441_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","volume":"67","author":"GA Kim","year":"2018","unstructured":"Kim GA, Lim YS, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67:945\u2013952","journal-title":"Gut"},{"issue":"2","key":"10441_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12072-008-9065-2","volume":"2","author":"SK Sarin","year":"2008","unstructured":"Sarin SK, Kumar M. Should chronic HBV infected patients with normal ALT treated: debate. Hepatol Int. 2008;2(2):179\u2013184","journal-title":"Hepatol Int"},{"key":"10441_CR10","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","volume":"146","author":"HLY Chan","year":"2014","unstructured":"Chan HLY, Chan CK, Hui AJ, Chan S, Poordad F, Chang T-T, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014;146:1240\u20131248","journal-title":"Gastroenterology"},{"key":"10441_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12072-021-10153-2","volume":"15","author":"M Duan","year":"2021","unstructured":"Duan M, Chi X, Xiao H, Liu X, Zhuang H. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B. Hepatol Int. 2021;15:318\u2013327","journal-title":"Hepatol Int"},{"key":"10441_CR12","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/ajg.2009.187","volume":"104","author":"CM Chu","year":"2009","unstructured":"Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol. 2009;104:1693\u20131699","journal-title":"Am J Gastroenterol"},{"key":"10441_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s12072-021-10137-2","volume":"15","author":"A Koffas","year":"2021","unstructured":"Koffas A, Kumar M, Gill US, Jindal A, Kennedy PTF, Sarin SK. Chronic hepatitis B: the demise of the \u201cinactive carrier\u201d phase. Hepatol Int. 2021;15:290\u2013300","journal-title":"Hepatol Int"},{"issue":"10","key":"10441_CR14","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/hep4.1247","volume":"2","author":"N Ford","year":"2018","unstructured":"Ford N, Scourse R, Lemoine M, Hutin Y, Bulterys M, Shubber Z, et al. Adherence to Nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis. Hepatol Commun. 2018;2(10):1160\u20131167","journal-title":"Hepatol Commun"},{"issue":"6","key":"10441_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/cld.950","volume":"16","author":"Su","year":"2021","unstructured":"Su, et al. Withdrawal of nucleos(t)ide analogues in hepatitis B e antigen-negative patients: an Asian perspective. Clin Liver Dis (Hoboken). 2021;16(6):244\u2013248","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"4","key":"10441_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","volume":"15","author":"Kao","year":"2021","unstructured":"Kao, et al. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int. 2021;15(4):833\u2013851","journal-title":"Hepatol Int"},{"key":"10441_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.29640","volume":"68","author":"WJ Jeng","year":"2018","unstructured":"Jeng WJ, Chen YC, Chien RN, et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018;68:425\u2013434","journal-title":"Hepatology"},{"key":"10441_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1377\/hlthaff.2008.0905","volume":"30","author":"SE Post","year":"2011","unstructured":"Post SE, Sodhi NK, Peng CH, Wan K, Pollack HJ. A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Aff (Millwood). 2011;30:340\u2013348","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"10441_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/0971-5916.154476","volume":"140","author":"M Kumar","year":"2014","unstructured":"Kumar M, Sarin SK. Viral hepatitis eradication in India by 2080\u2014gaps, challenges and targets. Indian J Med Res. 2014;140(1):1\u20134","journal-title":"Indian J Med Res"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10441-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10441-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10441-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:45:31Z","timestamp":1675359931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10441-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10441"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10441-5","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"14 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Ankur Jindal and Shiv K. Sarin have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}